When playing the NK cell therapy card in glioblastoma, you can’t beat interleukin-21
Cancer Cell · 2024
DOI: 10.1016/j.ccell.2024.07.003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Cell, 2024. Verfasst von Nicholas D Huntington. Beteiligte Einrichtung: Biomedicine Discovery Institute and the Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC 3800, Australia; oNKo-Innat…. Hauptthemen laut MEDLINE: Glioblastoma, Killer Cells, Natural, Brain Neoplasms, Interleukins. Die Arbeit nennt 10 Literaturangaben. Gefördert von: National Health and Medical Research Council.
Abstract (Originalsprache)
Glioblastoma is the most common brain cancer, with a 5-year survival rate of less than 10%. This grim prognosis highlights the urgent need for novel therapeutic approaches. In this issue of Cancer Cell, Shanley et al.1 report an innovative engineering strategy to supercharge NK cell immunity against glioblastoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Biomedicine Discovery Institute and the Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC 3800, Australia; oNKo-Innate Pty. Ltd, Moonee Ponds, VIC 3039, Australia. Electronic address: nic…
Förderung
- National Health and Medical Research Council
Zitieren
APA
Huntington, N. D. (2024). When playing the NK cell therapy card in glioblastoma, you can’t beat interleukin-21. Cancer Cell. https://doi.org/10.1016/j.ccell.2024.07.003
Vancouver
Huntington ND. When playing the NK cell therapy card in glioblastoma, you can’t beat interleukin-21. Cancer Cell. 2024. doi:10.1016/j.ccell.2024.07.003
BibTeX
@article{Huntington2024,
author = {Huntington, Nicholas D},
title = {When playing the NK cell therapy card in glioblastoma, you can’t beat interleukin-21},
journal = {Cancer Cell},
year = {2024},
doi = {10.1016/j.ccell.2024.07.003}
}
EUVIMED